The benefits of naltrexone/bupropion (Mysimba) continue to outweigh its risks, despite ongoing uncertainty about long-term ...

The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive ...

PTC Therapeutics, Inc. announced today that the European Commission (EC) has adopted the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to ...

The CHMP's endorsement is based on outcomes from ... Discovered and developed by the company’s scientists, Rinvoq is a selective and reversible Janus kinase inhibitor under investigation for ...

The Purina Institute is excited to announce the Purina Institute Global Summit 2025, which will feature presentations from 20 ...

The Scientific Advisory Group (SAG) has been called in to assist the EMA’s CHMP human medicines committee in its review of the drug, which is vying to become the first disease-modifying therapy ...

The CHMP’s review of Vyjuvek was supported through the EMA’s PRIority MEdicines scheme, which provides enhanced scientific and regulatory support to medicines that have a particular potential to ...

National regulators rely on the CHMP’s scientific assessment to decide on the use of the medicine within their countries. The CHMP’s positive opinion of TAK-003 was supported by results across ...

Vertex Pharmaceuticals, a global biotechnology company that invests in scientific innovation to create transformative ... Committee for Medicinal Products for Human Use (CHMP) adopted a positive ...